RU2686670C2 - Лечение аллергического ринита с использованием комбинации мометазона и олопатадина - Google Patents

Лечение аллергического ринита с использованием комбинации мометазона и олопатадина Download PDF

Info

Publication number
RU2686670C2
RU2686670C2 RU2015128496A RU2015128496A RU2686670C2 RU 2686670 C2 RU2686670 C2 RU 2686670C2 RU 2015128496 A RU2015128496 A RU 2015128496A RU 2015128496 A RU2015128496 A RU 2015128496A RU 2686670 C2 RU2686670 C2 RU 2686670C2
Authority
RU
Russia
Prior art keywords
treatment
allergic rhinitis
specified
weeks
person
Prior art date
Application number
RU2015128496A
Other languages
English (en)
Russian (ru)
Other versions
RU2015128496A3 (enExample
RU2015128496A (ru
Inventor
ДЖОШИ Неелима ХАЙРАТКАР
Абхай КУЛКАРНИ
Динеш Прадип ВАЛ
Викрам Мансингх БХОСЛИ
Пиюш Агарвал
Патрик КЕОХЕЙН
Судиш К. ТАНТРИ
Чед О
Original Assignee
Гленмарк Спешиалити С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Гленмарк Спешиалити С.А. filed Critical Гленмарк Спешиалити С.А.
Publication of RU2015128496A publication Critical patent/RU2015128496A/ru
Publication of RU2015128496A3 publication Critical patent/RU2015128496A3/ru
Application granted granted Critical
Publication of RU2686670C2 publication Critical patent/RU2686670C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
RU2015128496A 2013-10-04 2014-10-03 Лечение аллергического ринита с использованием комбинации мометазона и олопатадина RU2686670C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN3174MUM2013 2013-10-04
IN3174MU2013 2013-10-04
PCT/IB2014/065035 WO2015049665A1 (en) 2013-10-04 2014-10-03 Treatment of allergic rhinitis using a combination of mometasone and olopatadine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2019104453A Division RU2799761C2 (ru) 2013-10-04 2014-10-03 Лечение аллергического ринита с использованием комбинации мометазона и олопатадина

Publications (3)

Publication Number Publication Date
RU2015128496A RU2015128496A (ru) 2017-11-13
RU2015128496A3 RU2015128496A3 (enExample) 2018-06-19
RU2686670C2 true RU2686670C2 (ru) 2019-04-30

Family

ID=51982657

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2015128496A RU2686670C2 (ru) 2013-10-04 2014-10-03 Лечение аллергического ринита с использованием комбинации мометазона и олопатадина

Country Status (21)

Country Link
US (1) US10646500B2 (enExample)
EP (2) EP2922553B1 (enExample)
JP (3) JP6419195B2 (enExample)
CN (2) CN112773808A (enExample)
ES (1) ES3071407T3 (enExample)
FI (1) FI2922553T3 (enExample)
HK (1) HK1215674A1 (enExample)
HR (1) HRP20260742T1 (enExample)
LT (1) LT2922553T (enExample)
MX (2) MX2015009429A (enExample)
MY (1) MY176808A (enExample)
PH (1) PH12015502302A1 (enExample)
PL (1) PL2922553T3 (enExample)
PT (1) PT2922553T (enExample)
RS (1) RS68262B1 (enExample)
RU (1) RU2686670C2 (enExample)
SI (1) SI2922553T1 (enExample)
SM (1) SMT202600244T1 (enExample)
UA (1) UA120587C2 (enExample)
WO (1) WO2015049665A1 (enExample)
ZA (1) ZA201504740B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9937189B2 (en) 2013-09-13 2018-04-10 Glenmark Specialty S.A. Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
US9370483B2 (en) 2013-09-13 2016-06-21 Glenmark Specialty S.A. Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
US10653661B2 (en) 2013-10-04 2020-05-19 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US10758550B2 (en) 2013-10-04 2020-09-01 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US10548907B2 (en) 2013-10-04 2020-02-04 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
MX2015009429A (es) * 2013-10-04 2015-10-09 Glenmark Pharmaceuticals Ltd Tratamiento de rinitis alergica utilizando una combinacion de mometasona y olopatadina.
US10016443B2 (en) 2013-10-04 2018-07-10 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US11679210B2 (en) 2014-10-03 2023-06-20 Glenmark Specialty S.A. Dispensing device and pharmaceutical composition for the treatment of rhinitis
CN115444851A (zh) * 2017-06-28 2022-12-09 格兰马克专业公司 用于治疗鼻炎的分配装置和药物组合物
CN111787954B (zh) * 2018-02-23 2023-09-05 格兰马克专业公司 使用莫美他松和奥洛他定的组合治疗儿科受试者的过敏性鼻炎
US12303635B2 (en) 2018-04-16 2025-05-20 Glenmark Specialty S.A. Dispensing device and pharmaceutical composition for the treatment of rhinitis

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040097474A1 (en) * 2002-11-12 2004-05-20 Alcon, Inc. Use of an anti-allergy agent and a steroid to treat nasal conditions
WO2009003199A1 (en) * 2007-06-28 2008-12-31 Cydex Pharmaceuticals, Inc. Nasal and ophthalmic delivery of aqueous corticosteroid solutions
RU2444351C2 (ru) * 2005-09-01 2012-03-10 Биолипокс Аб Композиция для лечения ринита и родственных заболеваний и способ ее получения

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8520662D0 (en) 1985-08-17 1985-09-25 Wellcome Found Tricyclic aromatic compounds
US4923892A (en) 1985-08-17 1990-05-08 Burroughs Wellcome Co. Tricyclic aromatic compounds
US6127353A (en) 1991-09-06 2000-10-03 Schering Corporation Mometasone furoate monohydrate, process for making same and pharmaceutical compositions
PE44995A1 (es) 1994-01-27 1995-12-18 Schering Corp Furoato de mometasona para el tratamiento de las enfermedades pulmonares y de las vias respiratorias
US5837699A (en) * 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases
EP1227812B1 (en) 1999-10-08 2007-04-18 Schering Corporation Topical nasal treatment using desloratadine and mometasone furoate
US7977376B2 (en) 2001-06-27 2011-07-12 Novartis Ag Olopatadine formulations for topical nasal administration
US8912174B2 (en) 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
PL1814538T3 (pl) 2004-11-24 2010-02-26 Alcon Inc Sposób dostarczania donosowego sprayu
EP1968548A2 (en) 2005-12-02 2008-09-17 Elan Pharma International Limited Mometasone compositions and methods of making and using the same
RU2434652C2 (ru) 2006-04-21 2011-11-27 Токо Якухин Когио Кабусики Кайся Емкость для текучей среды и система безвоздушного дозирования текучей среды с использованием упомянутой емкости
EP2318049A1 (en) * 2008-07-15 2011-05-11 Schering Corporation Intranasal compositions comprising a decongestant and a corticosteroid
US8642069B2 (en) 2008-08-27 2014-02-04 Alexander D. Goldin Composition and method for treating colds
BR112012001169A2 (pt) 2009-07-17 2016-03-01 Alcon Res Ltd sistema de pulverização nasal de olopatadina para crianças
CN102078326A (zh) * 2009-11-26 2011-06-01 天津金耀集团有限公司 含有聚维酮碘与糠酸莫米松的局部使用组合物
CN102078285A (zh) * 2009-11-26 2011-06-01 天津金耀集团有限公司 含有皮质激素和h1受体拮抗剂的鼻用原位凝胶
WO2011141929A2 (en) 2010-05-11 2011-11-17 Cadila Healthcare Limited Aqueous pharmaceutical compositions of fluticasone and olopatadine
JP5683719B2 (ja) 2011-01-04 2015-03-11 イスタ・ファーマシューティカルズ・インコーポレイテッドＩｓｔａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． ベポタスチン組成物
CN104755615A (zh) 2012-10-25 2015-07-01 诺维信公司 用于餐具洗涤的改进的方法
KR20140081925A (ko) 2012-12-12 2014-07-02 한미약품 주식회사 코르티코스테로이드, 항히스타민제 및 스테비아를 포함하는 고미 차폐된 약학 제제
UA116793C2 (uk) 2013-09-13 2018-05-10 Гленмарк Спешіалті С.А. Стабільна фармацевтична композиція з фіксованою дозою, що містить мометазон й олопатадин
US9370483B2 (en) 2013-09-13 2016-06-21 Glenmark Specialty S.A. Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
MX2015009429A (es) * 2013-10-04 2015-10-09 Glenmark Pharmaceuticals Ltd Tratamiento de rinitis alergica utilizando una combinacion de mometasona y olopatadina.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040097474A1 (en) * 2002-11-12 2004-05-20 Alcon, Inc. Use of an anti-allergy agent and a steroid to treat nasal conditions
RU2444351C2 (ru) * 2005-09-01 2012-03-10 Биолипокс Аб Композиция для лечения ринита и родственных заболеваний и способ ее получения
WO2009003199A1 (en) * 2007-06-28 2008-12-31 Cydex Pharmaceuticals, Inc. Nasal and ophthalmic delivery of aqueous corticosteroid solutions

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KAGAWA Y. et al. "Synergetic effects of prednisiline and olo[atadine on atopic dermatitis model of hairless mice". Pharmacology,2010;85(5):286-94, , найдено 08.06.2018 из PubMed PMID:20453552. *
KAGAWA Y. et al. "Synergetic effects of prednisiline and olo[atadine on atopic dermatitis model of hairless mice". Pharmacology,2010;85(5):286-94, реферат, найдено 08.06.2018 из PubMed PMID:20453552. *

Also Published As

Publication number Publication date
ES3071407T3 (es) 2026-06-23
LT2922553T (lt) 2026-07-10
EP4272839A3 (en) 2024-01-03
RS68262B1 (en) 2026-07-31
WO2015049665A1 (en) 2015-04-09
MY176808A (en) 2020-08-21
JP2018123157A (ja) 2018-08-09
ZA201504740B (en) 2016-10-26
RU2015128496A3 (enExample) 2018-06-19
US20150099725A1 (en) 2015-04-09
PH12015502302B1 (en) 2016-02-15
PH12015502302A1 (en) 2016-02-15
EP2922553A1 (en) 2015-09-30
SI2922553T1 (sl) 2026-07-31
UA120587C2 (uk) 2020-01-10
PL2922553T3 (pl) 2026-07-13
PT2922553T (pt) 2026-06-05
JP2016531949A (ja) 2016-10-13
HRP20260742T1 (hr) 2026-07-31
CN112773808A (zh) 2021-05-11
JP2020097624A (ja) 2020-06-25
MX2015009429A (es) 2015-10-09
CN105792828A (zh) 2016-07-20
RU2015128496A (ru) 2017-11-13
JP6768733B2 (ja) 2020-10-14
SMT202600244T1 (it) 2026-07-16
US10646500B2 (en) 2020-05-12
RU2019104453A (ru) 2019-03-28
FI2922553T3 (fi) 2026-06-15
MX2020003035A (es) 2020-07-22
JP6419195B2 (ja) 2018-11-07
HK1215674A1 (zh) 2016-09-09
EP2922553B1 (en) 2026-05-06
EP4272839A2 (en) 2023-11-08

Similar Documents

Publication Publication Date Title
JP6768733B2 (ja) モメタゾンおよびオロパタジンの組み合わせを使用するアレルギー性鼻炎の治療
US20200323843A1 (en) Use of levocetirizine and montelukast in the treatment of viral infection caused by coronavirus
Baroody et al. Oxymetazoline adds to the effectiveness of fluticasone furoate in the treatment of perennial allergic rhinitis
Kaiser et al. Fluticasone furoate nasal spray: a single treatment option for the symptoms of seasonal allergic rhinitis
US9023815B2 (en) Method for treating rhinitis and sinusitis by rhamnolipids
CN112773765A (zh) 治疗普拉德-威利综合征的方法
Okubo et al. Efficacy and safety of the emedastine patch, a novel transdermal drug delivery system for allergic rhinitis: phase III, multicenter, randomized, double-blinded, placebo-controlled, parallel-group comparative study in patients with seasonal allergic rhinitis
US10548907B2 (en) Treatment of allergic rhinitis using a combination of mometasone and olopatadine
Abelson et al. The added benefit of local Patanol therapy when combined with systemic Claritin for the inhibition of ocular itching in the conjunctival antigen challenge model
RU2799761C2 (ru) Лечение аллергического ринита с использованием комбинации мометазона и олопатадина
Neerati A textbook of pharmacology-III
CN115487180A (zh) 一种用于治疗变应性鼻炎的药物组合物
HK40095786A (en) Treatment of allergic rhinitis using a combination of mometasone and olopatadine
Ghimire et al. Comparative efficacy of steroid nasal spray versus antihistamine nasal spray in allergic rhinitis
WO2008028324A1 (fr) Nouvelle préparation de lévamisole pour traiter une rhinite allergique
Williams et al. Abnormal Pharyngeal pH Testing Predicts Response to Proton Pump Inhibitors in Patients with Chronic Cough and Laryngeal Complaints
HK1199815B (en) Levocetirizine and montelukast for the treatment of influenza and common cold
Werkhäuser et al. Clinical Study Treatment of Allergic Rhinitis with Ectoine Containing Nasal Spray and Eye Drops in Comparison with Azelastine Containing Nasal Spray and Eye Drops or with Cromoglycic Acid Containing Nasal Spray